Si desitges distingir els teus productes, serveis o tots dos dels d'una altra empresa, és possible que necessitis una marca o nom comercial. Descobreix què són, en què consisteix el seu procediment de registri i què implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tens un nou dispositiu, producte o procediment que resolgui un problema tècnic o tingui un avantatge pràctic, existeixen diferents formis de protegir-ho a Espanya i en altres països. Descobreix com fer-ho.
La teva innovació resideix en l'estètica, l'ornamentació o l'aparença del teu producte? Protegeix-la mitjançant un disseny industrial. Descobreix quins drets confereix el registri i com realitzar la tramitació.
Les indicacions geogràfiques protegeixen el nom d’un producte originari d’una zona geogràfica, a la qual li deu una determinada qualitat, reputació o una altra característica. Descobreix què són, en què consisteix el seu procediment de registre i quins beneficis atorguen.
Els patents publicades a tot el món són una valuosa font d'informació científica, tècnica i comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Si ets emprenedor/a o una empresa i vols potenciar i millorar la rendibilitat del teu negoci protegint de forma adequada els actius intangibles de la teva organització, en aquest espai trobaràs el necessari.
90
resultados
Última actualización
02/08/2026 [06:58:00]
Resultados 25 a 50 de 90
Resumen de: US20260201021A1
0000 Disclosed is a Fv-antibody having a specific binding ability to a cleavage site of a SARS-COV-2 spike protein by TMPRSS2. The Fv-antibody includes a peptide sequence of DPPPPAVAADV or CRDLLGVVRDF.
Resumen de: EP4775268A2
The invention relates to an anti-coronavirus polypeptide as well as derivatives and application thereof, provides the anti-coronavirus polypeptide, and provides cholesterol-containing derivatives of the polypeptide on the basis of the anti-coronavirus polypeptide. Particularly, the original strain and the variant strain of the SARS-CoV-2 have an unexpected inhibition effect, can be used for preparing medicines or vaccines for preventing or treating the new coronavirus, and have great prevention or treatment potential.
Resumen de: KR20260109386A
본 발명은 RGS2 및 SPL의 발현 수준을 측정할 수 있는 제제를 포함하는 SARS-CoV-2 감염증 중증도 진단용 조성물에 관한 것이다. 본 발명의 SARS-CoV-2 감염증 환자의 중증도 진단용 조성물을 이용하는 경우, 고혈압을 앓고 있는 SARS-CoV-2 감염증 환자의 중증질환 진행 여부에 대해 진단하는 데 사용될 수 있다.
Resumen de: US20260193327A1
0000 The invention is in the field of medical treatment, and relates to a method for treating SARS-CoV-2 infections. In particular, the present invention relates to methods for prophylactic and/or therapeutic treatment of betacoronavirus infections, in particular, SARS-CoV-2 infections by means of intranasal administration or oral inhalation of antibodies.
Resumen de: US20260193343A1
The present invention relates to an antiviral composition comprising Natural Killer (NK) cells as an active ingredient and, more particularly, to a composition for preventing or treating COVID-19 virus (SARS-COV-2) infection comprising NK cells as an active ingredient and a method for culturing lymphocytes comprising anti-COVID-19 virus NK cells.
Resumen de: US20260196317A1
A system and method that enables users to provide authenticated medical records (e.g., vaccination records, viral anti-body test results, etc.) to a third-party (e.g., a venue) to gain access to the third-party is provided. In this way, the third party may confirm that the user is sufficiently immune to a particular disease (e.g., COVID-19) and may thereby minimize the threat of the user introducing the contagious disease to the third party. The system includes a biometric data recognition system that authenticates the identity of a user, a medical records acquisition system that acquires the medical records of the authenticated user, and a system for the displaying or otherwise providing the medical records to the third-party for review. The system also includes a system identification card that includes the user's contact information, alphanumeric characters associated with the user's driver's license number, medical records of the user, and other elements.
Resumen de: US20260193724A1
0000 A method for the detection of SARS-CoV-2 in a sample based on reverse transcription loop-mediated isothermal amplification (RT-LAMP) of a target nucleic acid sequence. The RT-LAMP amplicons are detected by gold nanoparticles (AuNPs) functionalized with a probe specific for regions of the target sequence. Kits for the detection of SARS-CoV-2 in a sample are also provided wherein the kit comprises a reverse transcriptase, a polymerase, a primer set for reverse transcription loop-mediated isothermal amplification (RT-LAMP) of the target sequence in a SARS-CoV nucleic acid sequence and variants thereof, and a conjugated nanoparticle solution comprising gold, water, and a probe sequence that is at least 85% identical to SEQ ID No.: 1.
Resumen de: US20260193700A1
The invention describes a kit for detection of a target polynucleotide using a CRISPR effector system that comprises CAS9 from Francisella novicida, a synthetic sgRNA and a detection scheme based on binding and subsequent enzymatic cleavage of the target polynucleotide. The invention also describes a method for detection of a target polynucleotide using the kit. The kit can be applied to both pathogenic and non-pathogenic polynucleotides and can be used to distinguish polynucleotides different by a single mismatch without the need for sequencing. The kit can also be used for detection of COVID-19. The kit is economical, easy to assemble and provides a robust and rapid readout that can be appropriately adapted for point of care applications.
Resumen de: WO2026147882A1
The present invention is generally directed to a potent therapy for SARS-CoV-2 (CoV2) disease using pharmaceutical composition disclosed herein. Provided a new combinatorial drag or a new pharmaceutical composition comprising compound of Formula (II-I-W-B), and their use for the treatment or prevention of coronavirus infections, particularly the use for the treatment or prevention of infections caused by SARS-CoV-2 and mutants thereof.
Resumen de: WO2026148353A1
Provided are methods of suppressing an anti-oncolytic virus (anti-OV) antibody response to an oncolytic virus (OV) therapy. The methods comprise administering a B cell-depleting agent to a subject (e.g., a human subject) prior to and/or concurrently with administration of a therapeutic OV to the subject. Non-limiting examples of B cell-depleting agents include those that target CD19 or CD20. In some instances, a B cell-depleting agent comprises or consists of an antibody. In certain embodiments, the therapeutic OV administered to the subject is from the family Poxviridae, Herpesviridae, Adenoviridae, Paramyxoviridae, Rhabdoviridae, Reoviridae, Picornaviridae, Parvoviridae, or Coronaviridae. According to some embodiments, the B cell-depleting agent is administered (e.g., only administered) prior to and/or concurrently with an initial administration of the therapeutic OV to the subject. OV therapies of interest include, but are not limited to, OV cancer therapies.
Resumen de: WO2026148343A1
Compositions and methods for protecting against a wide spectrum of viral and bacterial infections, including Covid-19, and for treating established infection and infectious inflammation are described. The composition includes a novel combination of vitamins, minerals, nutraceuticals, and phytochemicals, which may be compounded as a pill, tablet, powder, capsule or liquid to be taken orally or via other administration routs one or more times per day, to serve as immune boosters, antibacterial agents, and antiviral agents along with providing anti-inflammatory effects in humans and animals.
Resumen de: EP4772515A1
The present invention belongs to the field of pharmaceutical technology and relates to a salt of a cyclic carbonate nucleoside compound, its crystal forms, preparation methods, and applications. The salt of the cyclic carbonate nucleoside compound has the structure shown in Formula I. When Y is hydrobromic acid and n=1, the salt of this nucleoside compound exists as Crystal Form A or Crystal Form B. Crystal Form A has advantages such as good physical and chemical stability, good solid properties, good water solubility, low hygroscopicity, and high oral bioavailability. It can be used to prepare drugs for treating and/or alleviating related diseases caused by viruses (particularly novel coronavirus, feline infectious peritonitis virus, respiratory syncytial virus, porcine epidemic diarrhea virus, feline calicivirus, etc.).
Resumen de: KR20260104317A
본 발명은 SARS-CoV-2 mRNA 백신 접종에 의해 발생되는 대상체의 부작용 예후 예측용 조성물 및 이를 포함하는 키트 및 SARS-CoV-2 mRNA 백신 스크리닝용 조성물에 관한 것이다. 구체적으로, 본 발명은 비만 또는 당뇨병 환자에서 SARS-CoV-2 mRNA 백신 접종으로 인한 부작용과 GSTP1 유전자가 연관이 높음을 확인하고, 이를 이용하여 SARS-CoV-2 mRNA 백신 접종에 의해 발생되는 대상체의 부작용 예후 예측용 조성물 또는 SARS-CoV-2 mRNA 백신 스크리닝용 조성물을 제공하고자 한다.
Resumen de: EP3913069A1
0001 The invention relates to a diagnostic kit for multiple detection of 4 viruses of the Family Coronaviridae: HCoV, SARS-CoV, MERS-CoV and the SARS-CoV-2 viral strain that has caused a pandemic of the disease known as COVID-19. The kit uses a "One-Step" approach with quantitative gene amplification after backward transcription of the viral genome (rRT-PCR). 0002 In order to avoid potential false negatives, the invention contains a double control using Porcine Epidemic Diarrhoea Virus (PEDV -CoV) and Ribonuclease P (RNase P-RP).
Resumen de: WO2026142889A1
Disclosed herein are methods for the treatment of cancer and inflammatory-based diseases and disorders, such as coronavirus colds and as a therapy against COVID-19. ImmunoFolate has been shown to reduce the incidents of colds and flus. In one embodiment is a method of treating cancer comprising administration of ImmunoFolate. In another embodiment is a method of treatment inflammatory -based disease and disorders comprising administration of ImmunoFolate.
Resumen de: US20260183385A1
0000 Provided are a vaccine composition for pan-COVID-19 comprising a consensus sequence of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) variants.
Resumen de: WO2026138823A1
Provided are a coronavirus-targeting broad-spectrum binding-blocking protein and a use thereof. Specifically, provided is a novel coronavirus Spike protein (S protein)-targeting binding protein having ultra-high affinity, wherein the protein can bind to an RBD area of the S protein and can block binding of a novel coronavirus to an ACE2 receptor, thereby blocking the novel coronavirus from invading host cells. Also provided is a novel coronavirus S protein-targeting self-assembling trimeric protein having high affinity, wherein the protein exhibits broad-spectrum blocking protection activity against novel coronaviruses.
Resumen de: WO2026139703A1
The present invention relates to compounds for use in the treatment of a disease or condition caused by Zika virus, Dengue virus, West Nile virus, Chikungunya virus, O`nyong`nyong virus, Sindbis virus or SARS-CoV-2 virus.
Resumen de: WO2026141623A1
Provided is an antiviral drug that is effective against SARS-CoV-2. Provided are: a compound represented by formula (I) (in the formula, Ar and R are as defined in the specification); a salt thereof; a solvate of these; a prodrug of these; and an anti-SARS-CoV-2 drug comprising these.
Resumen de: US20260185108A1
0000 Levels of expression of antibiotic resistance genes are increased up to six-fold by inserting a proteasome-targeting tag into transgenes expressed in eukaryotic cells. Various selectable marker proteins are combined with different destabilization domains, leading to up to 70% increase in transgene expression. The increase in expression varies highly depending on the engineered construct and the lines cells used. Increase in expression drives exosome loading of cargo proteins in some aspects. By increasing expression and by editing trafficking signals of cargo proteins, proteins that normally locate to the ER can be trafficked to exosomes. This disclosure discloses efficient exosome delivery of a wide variety of engineered proteins, including modified antigen proteins of SARS-CoV-2 and influenza, and other proteins such as a modified alpha galactosidase A, an extracellular domain of vascular endothelial growth factor fused to a constant region of a human immunoglobulin heavy chain, and modified trastuzumab heavy and light chains.
Resumen de: US20260183383A1
The present disclosure relates to compositions and methods for vaccinating a subject against multiple SARS-CoV-2 variants that involves the making and delivery of extracellular vesicles expressing on their surface engineered spike protein and/or engineered nucleocapsid protein to the subject. The present invention also relates to compositions and methods for the design, preparation, manufacture, formulation, and/or use of spike-display and nucleocapsid-display vesicular vaccines designed to elicit strong humoral and cellular immune responses against multiple SARS-CoV-2 variants.
Resumen de: US20260183407A1
0000 The present invention relates to bifunctional compounds, which find utility to degrade and (inhibit) one or more of the following kinases: DYRK1A, DYRK1B, DYRK2, DYRK3, CLKI, CLK2, CLK3, CLK4, and HASPIN. In particular, the present invention is directed to compounds, which contain on one end an E3 ubiquitin ligase binding moiety which binds to an E3 ubiquitin ligase and on the other end a moiety which binds one or more of the following kinases: DYRK1A, DYRK1B, DYRK2, DYRK3, CLK1, CLK2, CLK3, CLK4, and HASPIN, such that the one or more kinases is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of the one or more kinases. The bifunctional compounds serve as therapeutics for the treatment of Alzheimer's disease, down syndrome, diabetes, an autoimmune disease, an inflammatory disorder (e.g., airway inflammation, osteoarthritis (e.g., knee related osteoarthritis)), cancer (e.g., glioblastoma, prostate cancer, metastatic breast cancer, metastatic lung cancer, multiple myeloma, secondary metastatic tumors of the brain, colorectal cancer), a viral infection (e.g., SARS-COV-2 infection (e.g., COVID-19)), and other diseases.
Resumen de: KR20260101878A
본 발명은 황기 및 단삼 혼합 추출물을 유효성분으로 포함하는 만성 코로나19 증후군의 예방, 개선 또는 치료용 조성물에 관한 것으로, 코로나 바이러스 감염 후 브레인포그(brain fog)를 나타내는 환자가 본 발명의 황기 및 단삼 혼합 추출물을 복용한 후, 동기부여 능력, 집중력, 기억력 및 브레인포그 VAS(Visual Analog Scale) 상태 변화가 통계적으로 유의미하게 개선된 효과가 있으며, 현저하게 저하된 혈중 코티졸 수치가 증가되는 효과가 우수하므로, 만성 코로나19 증후군의 예방 및 치료용 의약품 또는 만성 코로나19 증후군 예방 및 개선용 건강기능식품으로 유용하게 사용될 수 있다.
Resumen de: WO2025137284A2
Disclosed are monoclonal antibodies, antigen binding fragments, and multi-specific antibodies that specifically bind a coronavirus spike protein, such as SARS-CoV-2. Also disclosed is the use of these antibodies and multi-specific antibodies for inhibiting a coronavirus infection, such as a SARS-CoV-2 infection. In addition, disclosed are methods for detecting a coronavirus, such as SARS-CoV-2, in a biological sample, using the disclosed antibodies and multi-specific antibodies.
Nº publicación: US20260177549A1 25/06/2026
Solicitante:
KEPHERA DIAGNOSTICS LLC [US]
Kephera Diagnostics, LLC
Resumen de: US20260177549A1
0000 Provided herein are methods, diagnostic instruments, and kits for detecting the presence or absence of an analyte associated with a disease in a subject. In some embodiments, the disease is Lyme disease, SARS-CoV-2, or a human immunodeficiency virus infection.
BOPI
Sede Electrónica
